2023-01-06
source from:The pharma letter
Metabolic and digestive disease specialist HighTide Therapeutics has raised S107 million in aseries C financing led by China's TCM Healthcare Fund, with money also from Yuexiu Fundand Yuthai Fund.
The company, which has a footprint in both China and the USA, is working on multifunctionaltherapies, including lead candidate HTD801, a first-in-class candidate for conditionsincluding type 2 diabetes and non-alcoholic steatohepatitis (NASH).
HighTide will use the money to advance clinical development as well as commercializationand business development.